2 strong blue chip ASX shares rated as buys by brokers

These 2 blue chip ASX shares are rated as buys by brokers. One of those ideas is biotech healthcare giant CSL Limited (ASX:CSL).

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Blue chip ASX shares can make good investments and some brokers have been scouring the market for the best ones to own.

The idea is that the broker will try to find the opportunities that might do well over the next 12 months – so then a price target is assigned. The bigger the price target, the stronger the return might be over the next year.

These two blue chip ASX shares are ones that leading brokers like:

best fintech asx shares represented by businessman flexing biceps

Image source: Getty Images

CSL Limited (ASX: CSL)

CSL is actually one of the biggest blue chip shares on the ASX. It has a market capitalisation well over $100 billion.

One of the brokers that likes the CSL share price right now is UBS. Whilst the interim report was strong, the broker doesn't think the following six months will be as good.

A key reason for the weaker expectation is that plasma collections are suffering and may not turn around until near the end of FY21.

One of the things that may help CSL is when COVID-19 vaccines have been deployed. However there is a while to go with this.

The blue chip ASX share is reporting some strength in its Seqirus business which CSL said delivered an exceptionally strong performance in the first six months of the financial year.

CSL did say that its performance is being supported by its diversified and resilient business model.

In the first half of FY21 it made $1.81 billion of net profit after tax (NPAT). Full year profit for FY21 is expected to be between $2.17 billion to $2.265 billion, which would be growth of up to 8% in constant currency terms, despite all of the impacts.

UBS has a price target of $310 for CSL shares, which would be growth of almost 30%.

Fortescue Metals Group Limited (ASX: FMG)

Fortescue is now one of the world's biggest iron ore miners and it's still rated as a buy by the brokers at Macquarie Group Ltd (ASX: MQG).

The blue chip ASX share is benefiting from the high iron ore prices and this is sending the net profit surging higher.

In the FY21 half-year result, revenue jumped 44% to $9.3 billion, underlying earnings before interest, tax, depreciation and amortisation (EBITDA) rose 57% to $6.6 billion and net profit after tax grew 66% to $4.08 billion. This funded a 93% increase of the dividend to AU$1.47 per share.

Fortescue has announced it plans to shift its business to greener initiatives sooner than expected with a goal of being carbon neutral by 2030.

Some of the plans include green hydrogen, renewable energy and green ammonia. It's looking for these types of projects across Australia and the world. Fortescue is looking to reduce its own footprint with getting rid of diesel consumption.

Macquarie doesn't think that FY22 will be as strong as FY21. So, for FY22, Macquarie is predicting that Fortescue can generate $2.42 of earnings per share (EPS) and that it's going to pay a dividend of $1.94 per share. That would translate into a forward grossed-up dividend yield of 13.6%. Macquarie has a price target of $25.50 for Macquarie. 

Tristan Harrison owns shares of Fortescue Metals Group Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Blue Chip Shares

Couple looking at their phone surprised, symbolising a bargain buy.
Blue Chip Shares

Are these ASX blue chips now too cheap to ignore?

Let's see why these shares could be seriously undervalued at current levels.

Read more »

A woman gives two fist pumps with a big smile as she learns of her windfall, sitting at her desk.
Blue Chip Shares

3 reasons to buy Wesfarmers shares today

The retail conglomerate is a no-brainer buy in my book.

Read more »

ASX shares buy Street signs stating 'Winners' and 'Losers' in front of urban backdrop
Blue Chip Shares

How are these 5 ASX share giants really tracking in 2026?

Some are struggling, while others are thriving, proving that opportunity is never far away.

Read more »

Happy work colleagues give each other a fist pump.
Blue Chip Shares

My best blue-chip ASX 200 buys for April

Looking for quality in uncertain markets? These three ASX 200 shares stand out to me.

Read more »

A woman scratches her head, thinking is this a no-brainer?
Healthcare Shares

Does this ASX 200 stock's fall make it a no-brainer buy?

Despite a major transformation, this stock is down more than 20%. Is this an opportunity?

Read more »

A happy woman stands outside a building looking at her phone and smiling widely.
Blue Chip Shares

I think smart investors should buy these ASX 200 blue-chip shares with $10,000

Looking for ideas? Here are three ASX 200 blue chips that could help build long-term wealth.

Read more »

A woman has a thoughtful look on her face as she studies a fan of Australian 20 dollar bills she is holding on one hand while he rest her other hand on her chin in thought.
Blue Chip Shares

Would I buy BHP, CBA, and CSL shares today?

These three ASX 200 leaders have taken different paths lately. Here’s how I’d think about them right now.

Read more »

A man looking at his laptop and thinking.
Blue Chip Shares

3 top blue-chip ASX 200 shares that look dirt cheap right now

A buying opportunity could have opened up for patient investors.

Read more »